HIMSS CEO announces retirement at end of 2017

H. Stephen Lieber, president and CEO of the Healthcare Information and Management Systems Society (HIMSS), will be retiring at the end of 2017.

“HIMSS has seen tremendous growth in size, reach and influence during Steve’s leadership,” said Sebastian Krolop, MD, HIMSS Board of Directors Chair. “Steve has provided the right balance of strategic and operational leadership necessary for HIMSS to transform from a small, U.S.-only based professional society to a large, globally focused diversified organization. I would therefore like to take this opportunity to express my deepest gratitude to Steve for his passion, constant dedication and outstanding efforts.”

Lieber has been a member of many organizations such as the American Society of Association Executives and Association Forum of Chicagoland as a past chairman, has been awarded life membership at the American Hospital Association and the American Society of Healthcare Risk Management, the Board of Directors of HIMSS and has been a Certified Association Executive since 1994.

“The past 17 years at HIMSS have been the most exciting and rewarding time of my professional life,” said Lieber. “I feel that our work at HIMSS has resulted in considerable improvements to the quality of care delivered to patients, to the safety of the treatments they receive and to the value of care provided. I hope that, in some way, I can continue this work of making care better and safer through information technology.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.